CTOs on the Move

Aligos Therapeutics

www.aligos.com

 
Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aligos.com
  • 1 Corporate Dr
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Aligos Therapeutics raised $125M on 01/10/2020
Aligos Therapeutics raised $83.6M on 07/01/2021

Similar Companies

Vir Biotechnology

Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world`s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevai Labs

ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.

VEXIOM HOLDINGS CORPORATION

VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eiger BioPharmaceuticals

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.